Abbott Laboratories (ABT) : R.m.sincerbeaux Capital Management reduced its stake in Abbott Laboratories by 3.45% during the most recent quarter end. The investment management company now holds a total of 27,950 shares of Abbott Laboratories which is valued at $1,259,148 after selling 1,000 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Abbott Laboratories makes up approximately 1.21% of R.m.sincerbeaux Capital Management’s portfolio.
Other Hedge Funds, Including , Schnieders Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 2,735 additional shares and now holds a total of 69,934 shares of Abbott Laboratories which is valued at $3,150,527. Abbott Laboratories makes up approx 1.73% of Schnieders Capital Management’s portfolio.Mountain Pacific Investment Advisers Incid reduced its stake in ABT by selling 500 shares or 1.46% in the most recent quarter. The Hedge Fund company now holds 33,735 shares of ABT which is valued at $1,456,340. Abbott Laboratories makes up approx 0.16% of Mountain Pacific Investment Advisers Incid’s portfolio.A. D. Beadell Investment Counsel boosted its stake in ABT in the latest quarter, The investment management firm added 10,475 additional shares and now holds a total of 51,878 shares of Abbott Laboratories which is valued at $2,239,573. Abbott Laboratories makes up approx 1.79% of A. D. Beadell Investment Counsel’s portfolio. Longer Investments added ABT to its portfolio by purchasing 42,220 company shares during the most recent quarter which is valued at $1,800,683. Abbott Laboratories makes up approx 1.92% of Longer Investments’s portfolio.Sonora Investment Management reduced its stake in ABT by selling 26 shares or 4.01% in the most recent quarter. The Hedge Fund company now holds 622 shares of ABT which is valued at $26,180. Abbott Laboratories makes up approx 0.01% of Sonora Investment Management’s portfolio.
Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.